ALNYLAM PHARMACEUT revenue breakdown overview

ALNYLAM PHARMACEUT revenue for the last year amounted to 1.54 B CHF, the most of which — 1.54 B CHF — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 959.33 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought ALNYLAM PHARMACEUT 1.07 B CHF, and the year before that — 569.37 M CHF.